# DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen

> **NCT01785108** · PHASE2 · COMPLETED · sponsor: **Johnny Ludvigsson** · enrollment: 60 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** GAD-Alum (Diamyd) 20 µg
- **BIOLOGICAL:** GAD-Alum (Diamyd) 20 µg X 2
- **DRUG:** Vitamin D
- **DRUG:** Ibuprofen

## Key facts

- **NCT ID:** NCT01785108
- **Lead sponsor:** Johnny Ludvigsson
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-08-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785108, "DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01785108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*